AgeneBio’s Phase 2B Trial Shows AGB101 Slows Progression of Brain Atrophy in Patients with Mild Cognitive Impairment Due to Alzheimer’s Disease Who Are Non-Carriers of the APoE-4 Allele

• The Phase 2B trial showed 40% less clinical decline and significantly reduced atrophy of the entorhinal cortex, a key marker of disease progression, compared to placebo in ApoE-4 non- carriers with MCI due to AD • Patients were given a once-daily dose of AGB-101, a proprietary low-dose extended-release formulation of levetiracetam or placebo in…